跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前AI 评分45

PepGen Inc. 提交 8-K,披露第三季度财务结果及 FREEDOM2-DM1 二期试验数据

PepGen Inc. (0001835597) (Filer)

AI 导读

PepGen Inc. 于 11 月 10 日提交 8-K,宣布截至 9 月 30 日的第三季度财务结果及近期业务进展,并附上相关新闻稿。公司还宣布 FREEDOM2-DM1 10 mg/kg 队列的二期试验结果,并提交数据更新演示材料供投资者会议使用。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

PepGen Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41374

85-3819886

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

321 Harrison Avenue

8th Floor

Boston, Massachusetts

02118

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 797-0979

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common stock, par value $0.0001 per share

PEPG

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.

On November 10, 2026, PepGen Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 and other business updates and issued a press release titled “PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights.” A copy of the press release is furnished as Exhibit 99.1.

The information in Item 2.02 of this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On November 10, 2026, the Company issued a press release titled “PepGen Announces Positive Phase 2 FREEDOM2-DM1 10mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures.” A copy of the press release in connection with the announcement is being furnished as Exhibit 99.2 to this Form 8-K.

The information in Item 7.01 of this Form 8-K, including Exhibit 99.2, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

A copy of the Company’s presentation titled “FREEDOM2-DM1, 10 mg/kg MAD Cohort Data Update,” is filed hereto as Exhibit 99.3 to this Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors from time to time.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits

Exhibit Number

Description

99.1

Press release issued by PepGen Inc. on November 10, 2026 titled “PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights”

99.2

Press release issued by PepGen Inc. on November 10, 2026 titled “PepGen Announces Positive Phase 2 FREEDOM2-DM1 10mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures”

99.3

FREEDOM2-DM1, 10 mg/kg MAD Cohort Data Update Presentation, as of November 2026

104

Cover Page Interactive Data File (embedded within Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PepGen Inc.

Date:

November 10, 2026

By:

/s/ Noel Donnelly

Noel Donnelly, Chief Financial Officer


来源:SEC EDGAR · 本站存档